论文部分内容阅读
新近暴发的新冠病毒肺炎(COVID-19)已成为危害全球健康的紧急事件.现有证据表明,新冠病毒(SARS-CoV-2)与其他冠状病毒(如SARS-CoV和MERS-CoV)的基因序列具有相似性.因此,针对现存冠状病毒的引发疾病的机制研究和在治疗SARS时所取得的经验和教训,可咨今天对抗新冠病毒引发疾病的参考.COVID-19患者的临床病理特征提示患者在病情进展过程中通常会经历五个发展阶段:大量病毒感染、免疫系统抑制、细胞因子风暴、多器官损伤及后期的肺纤维化样改变,严重者常导致死亡.早期阻断疾病进展是取得治疗成功的关键.但是,目前尚无针对COVID-19的特效药物或疫苗,世界卫生组织(WHO)正敦促尽快建立新型预防和治疗策略.传统中医药(TCM)对于疫病的防治的实践已经积累了几千年的有用经验,它通过整体调节机体功能发挥疗效.在此次疫情中,中医药作为替代治疗或与西药联合使用,在疫情防控中发挥了重要的作用.本文总结了此次抗疫过程中中国国家和省级机构推荐使用的中药复方和中成药的潜在用途和治疗机制,以期发现其治疗COVID-19的潜在科学内涵.同时,整合应用多种组学及转化医学技术开展基础与临床研究有望进一步证实中药复方的治疗机制.“,”The recent coronavirus disease 2019 (COVID-19) pandemic outbreak has caused a serious global health emergency. Supporting evidence shows that COVID-19 shares a genomic similarity with other coron-aviruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), and that the pathogenesis and treatment strategies that were applied 17 years ago in combating SARS-CoV and other viral infections could be taken as references in today's antiviral battle. According to the clinical pathological features of COVID-19 patients, patients can suffer from five steps of progression, starting with severe viral infection and suppression of the immune system and eventually progressing to cytokine storm, multi-organ damage, and lung fibrosis, which is the cause of mortality. Therefore, early prevention of disease progression is important. However, no specific effective drugs and vaccination are currently available, and the World Health Organization is urging the development of novel prevention and treatment strategies. Traditional Chinese medicine could be used as an alternative treatment option or in combination with Western medicine to treat COVID-19, due to its basis on historical experience and holistic pharmacological action. Here, we summarize the potential uses and therapeutic mechanisms of Chinese herbal formulas (CHFs) from the reported litera-ture, along with patent drugs that have been recommended by institutions at the national and provincial levels in China, in order to verify their scientific foundations for treating COVID-19. In perspective, more basic and clinical studies with multiple high-tech and translational technologies are suggested to further confirm the therapeutic efficacies of CHFs.